SARS-CoV-2
-
healthACTIV-6 Trial: Metformin Reduces Clinician-Diagnosed Long COVID Risk
The ACTIV-6 randomized trial reveals metformin lowers clinician-diagnosed long COVID by 50% in immune outpatients, despite missing primary endpoints for patient-reported symptom prevention at six months.
-
healthLockdown-Born Children Show Persistent Drop in Food Allergies
A longitudinal study from Ireland reveals children born during COVID-19 lockdowns maintain lower food allergy rates at age five, likely due to reduced antibiotic exposure.
-
healthPollen Exposure Amplifies Coronavirus Spread in Nasal Cells, EAACI Study Finds
New research presented at EAACI 2026 reveals pollen weakens nasal antiviral defenses, increasing susceptibility to SARS-CoV-2 and common coronaviruses through altered immune pathways.
-
healthAI-Designed Universal Vaccine Successfully Completes First Human Clinical Trial
Researchers from Cambridge and Southampton unveil an AI-created universal vaccine targeting Sarbeco coronaviruses, marking a pivotal shift from reactive to proactive pandemic defense.
-
healthFirst AI-Designed Vaccine Passes Human Trial at Cambridge
Phase 1 trial shows AI-crafted antigen is safe and triggers broad coronavirus immunity, including against future bat-borne strains.
-
healthWorld-First AI-Designed Vaccine Passes Human Trial at Cambridge
An AI-engineered vaccine, developed at Cambridge, successfully completed a Phase I trial, triggering broad immunity against coronaviruses.
-
healthAI-Designed Vaccine Could Revolutionize Pandemic Defense
University of Cambridge researchers have used AI to create a universal vaccine technology, tested in humans against multiple coronaviruses.
-
healthNew COVID-19 Variant BA.3.2 Spreads Globally
BA.3.2, dubbed the 'cicada' variant, has been detected in 23 countries since its emergence in South Africa.